Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07
  • MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy M...

    2025-12-23

    MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy Modulation

    Executive Summary: MRT68921 is a nanomolar dual inhibitor targeting ULK1 and ULK2 autophagy kinases, critical for autophagy initiation (APExBIO product dossier). This compound blocks ATG13 phosphorylation and LC3 flux, providing robust autophagy inhibition in wild-type but not mutant (M92T) ULK1-expressing cells (Phadwal et al., 2025). Its selectivity profile shows >80% inhibition of TBK1/IKK and AMPK-related kinases, though LKB1 knockout studies confirm ULK1/2 as primary autophagy targets. MRT68921 is insoluble in water/ethanol, dissolving at ≥2.18 mg/mL in DMSO under mild warming and sonication. No in vivo or clinical data exist; it is recommended strictly for preclinical autophagy research.

    Biological Rationale

    Autophagy is a conserved catabolic process essential for eukaryotic cell homeostasis. It degrades misfolded proteins, damaged organelles, pathogens, and lipid droplets via double-membraned autophagosomes that fuse with lysosomes (Phadwal et al., 2025). In mammals and fish, autophagy regulates lipid metabolism and prevents lipotoxicity by limiting diacylglycerol and ceramide accumulation. The serine/threonine kinase ULK1 is a key initiator of this process, integrating signals from mTOR and AMPK pathways. Inhibition of ULK1/2 disrupts autophagy initiation, providing a mechanistic handle to interrogate downstream autophagic events. Understanding these pathways is crucial for research into metabolic diseases, cancer, and neurodegeneration where autophagy is dysregulated (Phadwal et al., 2025).

    Mechanism of Action of MRT68921

    MRT68921 (C25H34N6O·xHCl, MW 434.58) is a highly selective inhibitor of ULK1 (IC50 = 2.9 nM) and ULK2 (IC50 = 1.1 nM) kinases (APExBIO). ULK1/2 phosphorylate ATG13, a regulatory step required for autophagosome nucleation. MRT68921 blocks this phosphorylation and downstream LC3 lipidation (LC3 flux), effectively halting autophagy initiation in wild-type cells. In cells expressing a ULK1 M92T mutant, MRT68921 does not inhibit ATG13 phosphorylation, confirming target specificity. MRT68921 also inhibits TBK1/IKK and some AMPK-related kinases by >80%, but LKB1 knockout MEF studies show autophagy inhibition is not mediated by these off-targets. The compound is insoluble in water and ethanol, but can be solubilized at ≥2.18 mg/mL in DMSO with gentle warming and sonication. Its action is reversible and suitable for preclinical cell-based assays (EPG Labs, 2023).

    Evidence & Benchmarks

    • MRT68921 inhibits ULK1 with an IC50 of 2.9 nM and ULK2 with an IC50 of 1.1 nM under in vitro kinase assay conditions at 25°C, using ATP at Km concentration (APExBIO).
    • Blocks ATG13 phosphorylation and LC3 flux in wild-type but not M92T ULK1 mutant cells, establishing target specificity (Phadwal et al., 2025).
    • Inhibits TBK1/IKK and AMPK-related kinases >80% in biochemical panels; however, LKB1 knockout MEFs reveal autophagy inhibition is ULK1/2-dependent (EPG Labs).
    • MRT68921 is insoluble in water/ethanol but dissolves at ≥2.18 mg/mL in DMSO after gentle warming and sonication (product specification).
    • No in vivo or clinical data available for MRT68921; use is restricted to preclinical research (APExBIO).

    Compared to previous EPG Labs coverage that emphasized benchmark performance in cell-based assays, this article provides updated solubility parameters and clarifies off-target kinase inhibition boundaries.

    Applications, Limits & Misconceptions

    MRT68921 is designed for preclinical research applications focused on autophagy pathway modulation and mechanistic studies in mammalian and fish cell models. Researchers use this compound to dissect ULK1/2-dependent autophagy, validate assay specificity via ATG13 phosphorylation status, and measure LC3 flux. It is particularly valuable for comparative studies alongside mTOR inhibitors like rapamycin, which induce rather than inhibit autophagy (Phadwal et al., 2025).

    For advanced integration strategies and translational workflows, see Redefining Preclinical Autophagy Modulation, which this article extends by detailing precise kinase inhibition parameters and solubility considerations.

    Common Pitfalls or Misconceptions

    • MRT68921 is not effective in vivo or in clinical settings; no pharmacokinetic or safety data exist for animals or humans.
    • Inhibition of AMPK-related kinases by MRT68921 (>80%) does not mediate autophagy blockade; LKB1 knockout studies confirm ULK1/2 as the relevant targets (Mechanistic Insights, 2023).
    • Compound is insoluble in water and ethanol; improper preparation leads to assay variability (use DMSO at ≥2.18 mg/mL with warming/sonication).
    • Not suitable for studies requiring reversible autophagy induction; MRT68921 is a robust inhibitor, not an inducer like rapamycin (Phadwal et al., 2025).
    • Off-target effects possible at high concentrations; use recommended working concentrations to preserve specificity.

    Workflow Integration & Parameters

    MRT68921 is supplied by APExBIO as a hydrochloride salt (SKU: B6174) and should be stored at -20°C. Prepare stock solutions in DMSO at ≥2.18 mg/mL using brief warming (37°C) and ultrasonic treatment. Working concentrations in cell-based assays typically range from 10–500 nM; titration is recommended for each cell line. Confirm inhibition of autophagy by assessing ATG13 phosphorylation and LC3-II accumulation via immunoblotting. For mechanistic studies, include controls with ULK1 M92T mutants to confirm target engagement. Refer to MRT68921 and the ULK1/2 Axis for comparative workflow design; this article adds updated solubility and storage guidance.

    Conclusion & Outlook

    MRT68921 is a benchmark dual ULK1/2 kinase inhibitor for dissecting autophagy signaling in preclinical research. Its potency, selectivity, and detailed mechanistic validation make it a vital tool for studies targeting autophagy-dependent processes. Limitations include lack of in vivo/clinical data and the necessity for precise solution preparation. Future research may explore analogs with improved solubility or in vivo profiles to enable translational applications. For more information, visit the official MRT68921 product page.